Clinical Trial News

Amgen presents new data on IMDELLTRA (tarlatamab-dlle) at 2024 WCLC, showing potential for combination with PD-L1 inhibitor as first-line maintenance therapy in ES-SCLC and sustained safety and efficacy in previously treated ES-SCLC.

11/16 patients in Evaxion's phase 2 trial showed 69% Overall Response Rate with tumor reduction in 15/16 patients. Full data to be presented at ESMO 2024 and discussed in a webinar with Professor Georgina V. Long on September 18, 2024.

AbbVie presents new data on its ADC platform at ESMO 2024, including results from the PICCOLO trial on mirvetuximab soravtansine for platinum-sensitive ovarian cancer, PROs from the LUMINOSITY trial on telisotuzumab vedotin in advanced NSCLC, and safety/efficacy data from a Phase 1 study of ABBV-400 in pre-treated NSCLC and GEA patients.

Sinopharm's domestic monkeypox vaccine candidate cleared for clinical trials, marking China's first. Developed by Shanghai Institute of Biological Products, it's a replication-deficient MVA vaccine, similar to Jynneos. Preclinical studies show good immune protection in nonhuman primates. No approved monkeypox vaccine exists in China yet.

CytoDyn Inc. updates shareholders on significant progress, including FDA approval, clinical trials, and partnerships, focusing on leronlimab's potential in oncology, inflammation, and other therapeutic areas.

PDS Biotechnology to present updated data from the VERSATILE-002 trial on September 14, 2024, at the ESMO Congress 2024 in Barcelona, evaluating first-line treatment with Versamune® HPV in combination with KEYTRUDA® for HPV16-positive recurrent/metastatic HNSCC.

Cereno Scientific announced an article by BioStock featuring an interview with CEO Sten R. Sörensen on the Orphan Medicinal Product Designation for CS1 in PAH. The article is available [here](https://news.cision.com/cereno-scientific/r/biostock-has-published-an-article-on-the-approved-ompd-for-cs1-in-the-eu-including-an-interview-of-c,c4034854).

Illumina's TruSight Oncology Comprehensive test, approved by the FDA, profiles 517 genes to match cancer patients with targeted therapies or clinical trials, aiding in personalized treatment.

Deucrictibant effectively prevents and treats hereditary angioedema (HAE) attacks in clinical trials, with sustained reductions in attack rates and faster symptom relief. Pharvaris is advancing Phase 3 trials for both prophylactic and on-demand treatment formulations.

© 2024 Mashup Media, LLC. All rights reserved.